Please login to the form below

Not currently logged in
Email:
Password:

immuno-oncology

This page shows the latest immuno-oncology news and features for those working in and with pharma, biotech and healthcare.

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

The combination of Opdivo and Yervoy lies at the heart of much of Bristol-Myers Squibb’s ambition in immuno-oncology, and an FDA approval for the pairing in kidney cancer

Latest news

More from news
Approximately 58 fully matching, plus 200 partially matching documents found.

Latest Intelligence

  • Let’s change the conversation about cancer Let’s change the conversation about cancer

    The group discussed the impact of recent developments in cancer therapies, such as immuno-oncology (IO). ... Watch the full Switched Oncology Patient Experience focus group here or visit Switched Oncology for more information.

  • Deal Watch January 2018

    Licence. 339. TeneoBio/TESARO. Multi-specific antibodies for up to six undisclosed oncology targets using UniRat® platform and discovery engine TeneoSeek. ... used to progress the clinical development of the company's immuno-oncology antibody

  • The good, the bad and the ugly The good, the bad and the ugly

    Oncology. Oncology has long been a key area of profit opportunity, but the recent explosion of immuno-oncology treatments has further extended the possibilities for growth. ... The oncology market is certainly evolving. “Some of the most interesting

  • Accelerating innovation Accelerating innovation

    Leading this work is an agreement with Bristol-Myers Squibb to study a combination of Cabometyx and that firm’s blockbuster immuno-oncology drug Opdivo (nivolumab) and an agreement with Roche ... We are open to. more collaborations… potentially

  • European venture funding for the life science sector European venture funding for the life science sector

    Focus on immuno-oncology. Oncology and especially immuno-oncology continues to take the majority of the funding within biopharma and while this is an exciting field - the first CAR-T approval ... And within the specific field of AI/ML there is certainly

More from intelligence
Approximately 1 fully matching, plus 43 partially matching documents found.

Latest appointments

  • Redx Pharma appoints new chief medical officer Redx Pharma appoints new chief medical officer

    Dr Saunders has worked in the oncology field for over 25 years and has experience in all aspects of the clinical development of oncology drugs. ... He joins the UK biotech from Lytix Biopharma, a Norweigan immuno-oncology biotech, where he also served as

  • Targovax appoints Michael Bogenstaetter as chief business officer Targovax appoints Michael Bogenstaetter as chief business officer

    Targovax appoints Michael Bogenstaetter as chief business officer. He joins the immuno-oncology biotech from Interim Assignments.

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    Lilly bolsters its oncology team. Kimberly Blackwell is appointed VP early phase development, immuno-oncology. ... Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    BMS’ Dr Mike Burgees joins Turnstone Biologics. He joins the immuno-oncology group as its president of R&D. ... Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral immunotherapies and powerful

  • Turnstone Biologics bolsters leadership team Turnstone Biologics bolsters leadership team

    Canadian immuno-oncology company Turnstone Biologics has strengthened its leadership team with the addition of two new hires.

More from appointments
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest from PMHub

  • Video: Immuno-oncology therapies

    Video: Immuno-oncology therapies. Immuno-oncology therapies which harness the body’ s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. ... In this video Director Sue Marett discusses the opportunities

  • Video: Immuno-oncology therapies

    Video: Immuno-oncology therapies. Immuno-oncology therapies which harness the body’ s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. ... In this video Director Sue Marett discusses the opportunities

  • From promise to practice: immuno-oncology in action Part 3 - Emerging Markets

    From promise to practice: immuno-oncology in action Part 3 - Emerging Markets. ... Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

  • Focus on immunotherapies: special magazine from Blue Latitude Health

    In this supplementary issue, we’ re taking a special look at immunotherapies, and more specifically, the growing buzz around “ immuno-oncology” therapies. ... Key insights around positioning immuno-oncology products based on our hands-on experience

  • Focus on multiple myeloma treatment: Witnessing a transformation

    Focus on multiple myeloma treatment: Witnessing a transformation. Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading. I get very excited

More from PMHub
Approximately 15 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics